Observational studyReproductive biology and endocrinology : RB&E2022
Basal and dynamic relationships between serum anti-Müllerian hormone and gonadotropins in patients with functional hypothalamic amenorrhea, with or without polycystic ovarian morphology.
Observational study in Reproductive biology and endocrinology : RB&E, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- AMH in PCOS and Beyond-Rare Case Series.Diagnostics (Basel, Switzerland) · 2026Article
- Distinguishing Polycystic Ovary Syndrome Phenotype D from Functional Hypothalamic Amenorrhea with Polycystic Ovarian Morphology: Clinical and Hormonal Insights from a Pilot Retrospective Study.Journal of menopausal medicine · 2025Article
- Changes in anti-mullerian hormone levels after recovery from functional hypothalamic amenorrhea: a retrospective cohort study about women with and without polycystic ovarian morphology.Reproductive biology and endocrinology : RB&E · 2025Article
- Beyond ovarian Morphology: Integrative stress profiling for distinguishing polycystic ovary syndrome from functional hypothalamic amenorrhea.Comprehensive psychoneuroendocrinology · 2025Article
- Mental Health as Assessed by the Symptom Checklist 90 (SCL-90) Scores in Women with and Without Polycystic Ovary Syndrome.Journal of clinical medicine · 2025Article
- Functional hypothalamic amenorrhoea and polycystic ovarian morphology: a narrative review about an intriguing association.Human reproduction update · 2025Review
- Neuroendocrine disturbances in women with functional hypothalamic amenorrhea: an update and future directions.Endocrine · 2024Review
- The LH:FSH Ratio in Functional Hypothalamic Amenorrhea: An Observational Study.Journal of clinical medicine · 2024Article
- Prolactin levels in functional hypothalamic amenorrhea: a retrospective case-control study.Archives of gynecology and obstetrics · 2024Article
- Stress and polycystic ovarian morphology in functional hypothalamic amenorrhea: a retrospective cohort study.Reproductive biology and endocrinology : RB&E · 2023Article
- A case-control study about markers of stress in normal-/overweight women with polycystic ovary syndrome and in controls.Frontiers in endocrinology · 2023Article
- Prevalence of functional hypothalamic amenorrhea in a cohort of women referred because of polycystic ovary syndrome.Reproductive medicine and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate in women with functional hypothalamic amenorrhea (FHA), whether there is a difference between patients with and without polycystic ovarian morphology (PCOM) concerning the response to a gonadotropin releasing hormone (GnRH) stimulation test and to pulsatile GnRH treatment.
methodsIn a retrospective observational study, 64 women with FHA who underwent a GnRH stimulation test and 32 age-matched controls without PCOM were included. Pulsatile GnRH treatment was provided to 31 FHA patients and three-month follow-up data were available for 19 of these.
resultsSerum levels of gonadotropins and estradiol were lower in FHA women than in controls (p < 0.05). FHA patients revealed PCOM in 27/64 cases (42.2%). FHA patients without PCOM revealed lower anti-Müllerian hormone (AMH) levels than controls (median 2.03 ng/mL, IQR 1.40-2.50, versus 3.08 ng/mL, IQR 2.24-4.10, respectively, p < 0.001). Comparing FHA patients with and without PCOM, the latter revealed lower AMH levels, a lower median LH increase after the GnRH stimulation test (240.0%, IQR 186.4-370.0, versus 604.9%, IQR 360.0-1122.0; p < 0.001) as well as, contrary to patients with PCOM, a significant increase in AMH after three months of successful pulsatile GnRH treatment (median 1.69 ng/mL at baseline versus 2.02 ng/mL after three months of treatment; p = 0.002).
conclusionsIn women with FHA without PCOM, the phenomenon of low AMH levels seems to be based on relative gonadotropin deficiency rather than diminished ovarian reserve. AMH tended to rise after three months of pulsatile GnRH treatment. The differences found between patients with and without PCOM suggest the former the existence of some PCOS-specific systemic and/or intra-ovarian abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.